Q-omics provides the consensus-scored CYTOR profile across patient tissues and cancer cell-line models. CYTOR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CYTOR is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CYTOR RNA expression shows 18,525 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where CYTOR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYTOR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYTOR survival associations across molecular data types. CYTOR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYTOR RNA expression–survival associations across cancer types. High CYTOR expression shows unfavorable associations in UVM, ACC, KIRC, KIRP, BRCA and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CYTOR RNA expression.
This table summarizes CYTOR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYTOR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYTOR shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and LUAD. The HNSC box plot shows higher CYTOR RNA expression in tumor versus normal tissue (log2 FC = +2.005, t-test p < 0.001).
This table shows molecular features associated with CYTOR in patient tissues and cancer cell lines. In patient samples, CYTOR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
